The newsroom
Independent coverage from Hormone Journal — launches, policy, and analysis.
Featured · NewsMost people who stop GLP-1 drugs restart within a year, a 60,000-patient study found. Canadian patients face added barriers: patchy provincial coverage and supply gaps that can force unplanned breaks.
NewsMost people who stop GLP-1 medications restart within a year, a large US study found. Canadian patients face the same pattern, complicated by inconsistent provincial drug coverage.
NewsWomen with premature menopause (before 40) face a 12.3% higher hypertension risk. Canadian patients should ask their doctor about earlier blood pressure screening and hormone therapy eligibility.
NewsGLP-1 drugs raise hair loss risk by 37-68% relative to other diabetes medications, but absolute rates are low. Rapid weight loss, not direct follicle damage, appears to be the main driver.
NewsNew studies show GLP-1 drugs carry a real but low hair-loss risk. Health Canada has not issued guidance; Canadian patients should discuss the finding with their prescriber.
NewsThe UK banned domperidone in phaeochromocytoma patients after reports of severe hypertension. Health Canada has not yet acted. Canadian patients with adrenal tumour history should speak to their doctor now.
NewsThe largest review to date suggests GLP-1 drugs may ease binge eating disorder symptoms, but Health Canada has not approved them for this use and evidence remains limited.
NewsHealth Canada's July 2026 order lets it lean on foreign regulatory decisions to approve drugs faster. Hormone-therapy patients may benefit, but no specific HRT drugs have been named yet.
NewsHealth Canada approved 15 new drugs in Q2 2026. Two are directly relevant to hormone patients: Thyconvi for thyroid therapy and Lupin-Glucagon for pancreatic hormone emergencies.
NewsA large 2026 study found one in three women over 35 unsure if they are in perimenopause. Canadian patients face the same gaps, with uneven provincial access to informed care.
NewsCombining GLP-1 drugs (like semaglutide) with SGLT2 inhibitors (like empagliflozin) cut heart failure hospitalizations versus either drug alone in a 99,683-patient CMAJ meta-analysis, but evidence certainty was very low and no benefit appeared for heart attack, stroke, or kidney failure.
NewsHealth Canada has told doctors not to start new patients on TAVNEOS (avacopan) while it reviews whether flawed trial data undermines the drug's approval. Current patients should consult their physician before making any changes.
NewsResearchers writing in The Lancet want PCOS renamed PMOS to better reflect the condition's metabolic roots. Canadian regulators and the SOGC have not yet responded.
NewsResearchers writing in The Lancet propose renaming PCOS to PMOS to better capture its metabolic and hormonal nature. Health Canada and the SOGC have not yet issued guidance on the proposed change.
NewsHealth Canada approved Svemia, Canada's first generic semaglutide weight-loss injection, on June 30, 2026. Prices may fall significantly, but provincial coverage decisions are still pending.
NewsA large 2026 study found GLP-1 users had significantly higher rates of smell and taste disturbances. Absolute risk remains low, but Canadian patients and prescribers should be aware.
NewsA 10,000-woman study links hormone therapy use to better diet, activity, and sleep, but researchers say healthy-user bias, not the hormones, probably explains most of the difference.
NewsA major NEJM review published June 18, 2026 formalizes risk-stratified, personalized care for differentiated thyroid cancer. Canadian patients should ask their endocrinologist whether active surveillance or minimalist surgery applies to their tumour.
NewsA UK study found GLP-1 drugs improved testosterone and sperm quality in men with high BMI after 24 weeks. Canadian regulators have not approved these drugs for male fertility, and more trials are needed.
NewsSurgical menopause causes more severe vaginal dryness, painful intercourse, and urinary symptoms than natural menopause, a 2026 study of 400+ women found. Canadian patients should ask their clinician about GSM screening and treatment options before and after surgery.
NewsAstraZeneca's oral GLP-1 pill showed promising weight-loss trial results, but Health Canada has not approved it and Canadian access remains years off.
NewsAstraZeneca's oral GLP-1 pill showed promising Phase 2 weight-loss data in June 2026, but Health Canada has not reviewed it and it is not available to Canadians yet.
NewsOsteoporosis Canada says GLP-1 weight-loss drugs can accelerate bone and muscle loss. Canadian patients need monitoring, calcium, vitamin D, and resistance exercise alongside treatment.
NewsWomen with endometriosis or unexplained infertility may reach menopause years earlier than average, a new study finds, with direct implications for long-term health monitoring in Canada.
NewsGLP-1 microdosing is a social-media trend with zero clinical trial support. Health Canada has not approved it, and no standard dose definition exists.
LaunchesCanada approved two generic semaglutides in spring 2026. Felix Health is offering them at $150/month, well below the $200–$450/month brand-name range.